ISRCTN10841210已完成不适用
Does the addition of Recombinant Luteinising Hormone (recLH) (Luveris) to a regimen of Recombinant Follicle Stimulating Hormone (recFSH) (Gonal-F) and Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?
VU University Medical Centre (VUMC) (Netherlands)0 个研究点目标入组 600 人开始时间: 2006年2月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Age >35 years undergoing IVF or intracytoplasmic sperm injection (ICSI) for any indication
排除标准
- •Women with polycystic ovary syndrome (PCOS)
研究者
相似试验
招募中
不适用
The effect of luteinizing hormone-releasing hormone antagonist in the progression prostate cancer with initial luteinizing hormone-releasing hormone agonistprostate cancerJPRN-UMIN000009079M-CURE32
招募中
3 期
Detection of recombinant human luteinising hormone (rLH) as a doping agentACTRN12608000181303Sydney South Western Area Health Service (SSWAHS)64
已完成
4 期
The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)Pregnancy Result RapeNCT01016210The Baruch Padeh Medical Center, Poriya60
尚未招募
不适用
The effect on embryo-quality of rLH-addition to rFSH for controlled ovarian hyperstimulation in women with poor ovarian reservesubfertility1001470110013356NL-OMON31586Academisch Medisch Centrum220
已完成
不适用
Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSSOvarian Hyperstimulation SyndromeNCT02200952San Carlo Public Hospital, Potenza, Italy16